Infusion reactions to the chimeric EGFR inhibitor cetuximab–change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.

Resch G, Schaberl-Moser R, Kier P, Kopetzky G, Scheithauer W, Sliwa T, Greil R, Nösslinger T, Mayrbäurl B, Thaler J.

http://www.ncbi.nlm.nih.gov/pubmed/21239398